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Abstract
In recent years, the coexistence of sexual dysfunction (SD) and lower urinary tract 
symptoms (LUTS) has become a popular topic for researchers. Numerous clinical 
epidemiologic studies have been planned for this reason and have evaluated the rela-
tionship between these seemingly irrelevant urological conditions. The connection 
between SD and LUTS has already been acknowledged, and common pathophysi-
ological pathways have been recognized. In this chapter was attempted to evaluate the 
impact on patient’s quality of life (QoL), common pathophysiological pathways and 
therapy aspects of this condition. SD and LUTS are common problems among the 
general population and affect a great percentage of urological patients. It is a subject 
that affects the community in social, financial, and psychological terms. In this case, 
research for new treatment options has been triggered as phosphodiesterase type 5 
inhibitors established their role as the widely approved combination therapy.
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1. Introduction
In recent years, the coexistence of sexual dysfunction and lower urinary tract symp-
toms has become a popular topic for researchers. Numerous clinical epidemiologic 
studies have been planned for this reason and have evaluated the relationship between 
these seemingly irrelevant urological fields of study. In this chapter, an approach to 
these two fields, their impact on patients’ quality of life (QoL), common pathophysi-
ological pathways and therapy aspects are attempted. Both are common problems 
among the general population and affect a great percentage of urological patients. In 
this case, research for new treatment options has been triggered as phosphodiesterase 
type 5 inhibitors established their role as the widely approved combination therapy.
2. Lower urinary tract symptoms
Lower urinary tract symptoms (LUTS) are a common complaint in adult men 
and women with a major impact on quality of life (QoL) [1–4]. They can be divided 
into storage, voiding, and postmicturition symptoms [5]. LUTS are strongly associ-
ated with aging [1, 2] and also with a number of modifiable risk factors, suggesting 
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potential targets for prevention (e.g., metabolic syndrome) [6]. Most elderly men 
have at least one LUTS [2], which is often mild or not very bothersome [4, 7, 8]. 
LUTS progression is a dynamic procedure. LUTS may persist and upscale over long 
time periods, or they may retreat [2]. LUTS have usually been related to bladder 
outlet obstruction (BOO), which is often caused by an increase of prostatic volume, 
as a result of benign prostate hyperplasia (BPH) [3, 5]. On the contrary, numerous 
studies have shown that LUTS are often not related to the BPH [2, 9]. Bladder dys-
function may also cause LUTS, such as detrusor overactivity or overactive bladder 
syndrome (OAB), detrusor underactivity, and structural or functional abnormali-
ties of the urinary tract and its surrounding tissues [9]. Prostatitis may also cause 
the appearance of LUTS [10, 11]. Furthermore, there are some nonurological 
conditions that may be related to urinary symptoms, mainly to nocturia [2].
The definitions of the most common conditions related to LUTS are presented 
below:
• Acute retention of urine is defined as a painful and palpable bladder when the 
patient cannot urinate [5].
• Chronic retention of urine is defined as a nonpainful bladder, which remains 
palpable even though the patient has urinated. It may also be accompanied by 
incontinence [5].
• Bladder outlet obstruction (BOO) is characterized by reduced urine flow rate 
and increased detrusor pressure. It can be diagnosed by studying the synchro-
nous values of detrusor pressure and urine flow rate [5].
• Benign prostatic obstruction (BPO) is a form of BOO, diagnosed when the 
cause of outlet obstruction is known to be BPH [5].
• Detrusor overactivity (DO) is a urodynamic observation characterized by 
involuntary detrusor contractions during the bladder filling phase [5].
• Overactive bladder (OAB) syndrome is characterized by urinary urgency, with or 
without urinary incontinence, usually with increased daytime frequency and noc-
turia, and in this case, there is no proven infection or other obvious pathology [12].
Patient’s history must be assessed thoroughly [13–15]. A medical history aims to 
identify relevant comorbidities and potential causes, including medical and neuro-
logical diseases. Lifestyle habits, medication, emotional, and psychological factors 
must also be reviewed. When relevant, the sexual function should be assessed, pref-
erably with validated symptom questionnaires such as the International Index for 
Erectile Function (IIEF). The literature recommends, for male LUTS assessment, 
the use of validated symptom score questionnaire [13, 15]. Several questionnaires 
have been developed, which are sensitive to symptom changes. In this case, they are 
helpful in monitoring treatment approaches [16–22]. Symptom scores are helpful in 
quantifying LUTS and identifying the predominant symptoms. Nevertheless, they 
are not disease- or age specific.
3. Sexual dysfunction
It is difficult to identify the prevalence of sexual dysfunction in men, because 
there is no standard definition of sexual dysfunction (SD). Erectile dysfunction 
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(ED) is defined as the persistent inability to attain and maintain an erection suf-
ficient to permit satisfactory sexual performance [23]. Penile erection is a complex 
phenomenon, which implies coordination among the neurological, vascular, and 
smooth muscle compartment. It includes arterial dilation, trabecular smooth 
muscle relaxation, and activation of the corporal veno-occlusive mechanism [24]. 
ED may affect physical and psychosocial health. It might have a significant impact 
on the QoL of sufferers and their partners’ as well [25–27]. Therefore, ED should 
not be regarded only as a QoL issue, but also as a potential warning sign of cardio-
vascular disease (CVD), as it can be an early manifestation of coronary artery and 
peripheral vascular disease [28–30].
The pathophysiology of ED may be vasculogenic, neurogenic, anatomical, 
hormonal, drug-induced, and/or psychogenic [24]. Usually, many pathophysiol-
ogy pathways can be comorbid and concomitant, negatively impacting on erectile 
function. In most cases, ED is the result of more than one organic pathophysiologi-
cal element and, very often, a psychological component. ED was initially classified 
into three categories based on its etiology. These include organic, psychogenic, and 
mixed ED. Nowadays, these are recognized as two categories: the psychogenic and 
the mixed one, as any organic ED has an additional psychogenic impact that inter-
feres with the pathophysiology of ED and causes additional distress to the patient.
Epidemiological data have shown a high incidence and prevalence of ED world-
wide. The Massachusetts male aging study (MMAS) [25] reported, in noninstitu-
tionalized men aged 40–70 years in the Boston area, an overall prevalence of 52% 
ED. Prevalence for minimal, moderate, and complete ED was 17.2, 25.2, and 9.6%, 
respectively. In the Cologne study of men aged 30–80 years, the prevalence of ED 
was 19.2% [65]. The incidence rate of ED (new cases per 1000 men annually) was 
26 in the long-term data from the MMAS study [66] and 19.2 (mean follow-up of 
4.2 years) in a Dutch study [31].
ED shares common risk factors with CVD (e.g., obesity, diabetes mellitus, 
dyslipidemia, metabolic syndrome, lack of exercise, and smoking) [27, 32–34]. The 
association among ED and age, diabetes mellitus, body mass index (BMI) [35, 36], 
obstructive sleep apnea, and hyperhomocysteinemia has been established [37–39]. 
A number of studies have shown evidence that lifestyle modification [29, 40] and 
pharmacotherapy [40, 41] for CVD risk factors may also improve sexual func-
tion in men with ED. Epidemiological studies have also demonstrated consistent 
evidence for an association between LUTS and sexual dysfunction, regardless of 
age, other comorbidities, and behavioral factors [42]. The multinational survey 
on the aging male (MSAM-7) study (performed in France, Germany, Spain, Italy, 
the Netherlands, the USA, and the UK) investigated the relationship between 
LUTS and sexual dysfunction in over 12,000 men aged 50–80 years. From 83% 
of sexually active men, the prevalence of LUTS was 90%, with the prevalence of 
ED being 49%. The complete absence of erection was reported in 10% of patients. 
The prevalence of ejaculatory disorders has been reported in 46% of patients [43]. 
Association between chronic prostatitis or chronic pelvic pain syndrome (CP/
CPPS) and ED is confirmed [44].
Surgical interventions to the prostate also have an impact on erectile function 
according to the type of surgery that was performed [45]. Epidemiologically, there are 
other risk factors that potentially associate to ED, including psoriasis [46–48], gouty 
arthritis [49, 50], ankylosing spondylitis [51], nonalcoholic fatty liver [52], chronic 
liver disorders [53], chronic periodontitis [54], open-angle glaucoma [55], inflamma-
tory bowel disease [56], and complications following transrectal ultrasound (TRUS) 
guided prostate biopsy [57].
World Health Organization (WHO) and International Classifications of 
Diseases-10 (ICD-10) define female sexual dysfunction as “the various ways in 
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which an individual is unable to participate in a sexual relationship as she would 
wish” [58]. There are three categories of sexual dysfunction: female sexual interest-
arousal disorder, female orgasmic disorder, and genito-pelvic pain-penetration 
disorder [59]. It is estimated that 10% of women suffer from female sexual interest-
arousal disorder and 3.5–35% present orgasmic problems [60].
Validated psychometric questionnaires, such as the International Index for Erectile 
Function (IIEF) [61] or the sexual health inventory for men (SHIM) [62], are the 
assessment tools needed in different sexual function domains (i.e., erectile function, 
sexual desire, intercourse, orgasmic function, and overall satisfaction), as well as for the 
potential impact of a specific treatment modality. The use of the erectile hardness score 
for the assessment of penile rigidity in practice and in clinical trial research is supported 
by psychometric analyses [63]. Patients should be screened for symptoms of possible 
hypogonadism (testosterone deficiency), libido, fatigue, cognitive impairment, and 
LUTS. Even though LUTS does not represent a contraindication to treat a patient for 
late-onset hypogonadism, screening for LUTS severity is clinically relevant [64].
4. The relationship between ED and LUTS
A lot of epidemiological studies demonstrate the coexistence of ED and LUTS. It 
is also proven that the existence of LUTS is a risk factor for ED. The patient’s age and 
the severity of LUTS are independent prognostic factors for ED, as well. Although it is 
not clear if LUTS lead to ED, or ED results to LUTS, or these conditions are just coex-
isting, their relation is very narrow and clear, especially in older patients. Therefore, 
men who suffer from LUTS should be checked for ED and men who present ED 
should be evaluated for LUTS. There are four theories that try to correlate LUTS with 
ED. These theories include deregulation of NO/NOS system, increased sympathetic 
tone (autonomic hyperactivity (AH)), up-regulation of Rho-kinase, and chronic 
hypoxia. Common vascular risk factors can combine and support these theories.
4.1 Alteration in nitric oxide (NO)
The role of nitric oxide (NO) in erectile function is well known as the main 
regulator of penile corporal smooth muscle relaxation and resultant erection. The 
decrease in NO/cyclic guanosine monophosphate (cGMP) has the effect of reduc-
tion in NO synthase (NOS) due to endothelial dysfunction. Luck or reduction of 
smooth muscle relaxation of the bladder neck, prostate and urethra may lead to 
LUTS. The NO system has been shown to be down-regulated in the transition zone 
of the prostate in BPH when compared with normal controls [67, 68].
4.2 Autonomic hyperactivity (AH)
AH, as a component of the metabolic syndrome, refers to dysregulation of 
sympathetic and parasympathetic tone. Increased sympathetic tone results in flac-
cidity and antagonizes penile erection, due to vasoconstriction. Parasympathetic 
activation can lead to prostate smooth muscle contraction (due to activation of the 
M2 receptors), so nonrelaxing bladder neck, prostatic urethra, and pelvic floor may 
lead to LUTS [67, 68].
4.3 RhoA/rho-kinase-calcium-sensitizing pathway
Smooth muscle tone is adjusted commonly not only through the calcium-
dependent mechanism, but also through the activity of RhoA/ROCK calcium 
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pathway. Activation of RhoA-ROCK pathway can affect smooth muscle relaxation 
and finally increase ED and LUTS. Therefore, penile RhoA/ROCK signaling was 
increased in pathologic situations associated with ED, like diabetes and involuntary 
bladder contractions were associated with increased signaling of the muscarinic 
receptor-activated RhoA/ROCK pathway. Increase in RhoA/ROCK was dem-
onstrated in corpora cavernosa and bladder of spontaneously hypertensive rats 
(SHR), a rat strain genetically prone to develop BPH and OAB. The inhibition of 
ROCK reduces bladder hyperactivity, limits contractions in bladder strips from 
SHR, and improves erectile function [67, 68].
4.4 Pelvic atherosclerosis
Atherosclerosis of the bladder, prostate, and penis serves an extra assumption 
linking LUTS with ED. The theory claims that the risks for ED (smoking, hyper-
tension, hypercholesterolemia, and diabetes mellitus) also affect on LUTS. An 
epidemiologic study was published that supports this theory, all men and women 
who had two risk factors of atherosclerosis (diabetes mellitus, hypertension, 
hyperlipidemia, and nicotine use) and had a statistically higher International 
Prostate Symptom Score (IPSS) compared with those with one or no risk factors 
at all. Smooth muscle changes in the prostate, bladder, and penis of animal models 
of hypercholesterolemia and pelvic ischemia are quite similar. Hypoxia drives to 
overexpression of TGFb1, and converted prostanoid production has been suggested 
as potential mechanisms. Similarly, penile ischemia leads to smooth muscle loss 
in it and ends up with ED. Likewise, the loss of smooth muscle in the bladder may 
decrease compliance and increase the symptoms of LUTS. Additionally, bladder 
ischemia either from BOO or pelvic vascular disease would result in bladder smooth 
muscle loss with the resultant replacement of collagen deposition and fibrosis as 
well as loss of compliance, overactivity, and impaired contractility. Loss of smooth 
muscle in the prostate can induce a less distensible urethra, a decreased urinary flow 
rate, increased flow resistance, and worsening LUTS. Pelvic atherosclerosis associ-
ated with the previously described theories, as pelvic ischemia/atherosclerosis is a 
component of the metabolic syndrome/AH, up-regulates Rk activity, and reduces 
NOS expression. [35, 67, 68].
5. Multifactorial interaction between LUTS and ED
LUTS are significant indicators of a disease when the patient, caregiver, or part-
ner realizes it, and change of them may lead him/her to find help from profession-
als. It is also known (from the 6th International Consultation on Incontinence 2016) 
that from overall world’s population, 46% (of the adults >20 years) experience 
LUTS, 11.8% suffer from OAB symptoms, 8% complain of some type of urinary 
incontinence (UI), and 4% of severe stress urinary incontinence (SUI). Urinary 
incontinence is associated with reduced QoL, higher rates of depression, reduced 
work productivity, and decreased enjoyment of sexual activity [35, 69].
It is well known that sexual life, behavior, and relationships are very impor-
tant for a good and healthy life, and they are affected by attitudes, social models 
and overall health. For sexual health many aspects are necessary and not only 
the absence of infirmity, disease or dysfunction. Sexual practice and habits have 
changed a lot over the last years, it is over also known that the sexual frequency and 
different practices are reducing with age. On the other hand, some sexual behaviors 
are more common in our days, like anal sex. These changes are more likely to be 
attributed to educational status, rather than economic status [69].
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From a physiological prospect, the functions of pelvic organ functions are 
related as there is a direct relationship with the neuronal network of the pelvis that 
includes bladder, bowel, and sexual functions. Furthermore, vascular, hormonal, 
cellular, and other factors comprehensively affect pelvic organ functions. LUTS and 
ED in males share common pathophysiological pathways [4].
6.  Effects of LUTS/incontinence on male sexual function: 
epidemiological data
Many large studies over the last years have proved the coexistence of SD in men 
with storage and voiding LUTS. Statistics from the Health Improvement Network 
database showed that from 11,327 men in the UK, there was a rise in the overall 
prevalence of recorded SD from 1.7% in 2000 to 4.9% in 2007. The odds ratio (OR) 
for ED was 3.0 (2.6–3.4) for storage LUTS, 2.6 (2.4–2.7) for voiding LUTS, and 4.0 
(3.4–4.8) for voiding and storage LUTS. The EpiLUTS study (a cross-sectional, 
population-representative survey in the UK, Sweden, and the USA with 6326 men) 
show off an impact of OAB on sexual health. Both OAB wet and OAB dry were 
associated with poor sexual health, diminished enjoyment of sex (P < 0.0001), 
and decreased sexual activity. OAB dry/wet was very significant predictors of ED 
and ejaculatory dysfunction (EjD) in men. According to a study by Rosen et al., 
the attendance and severity of LUTS are independent risk factors for SD in older 
men [69].
LUTS are common in older men. While LUTS have a multifactorial etiology, 
BOO/BPH has traditionally been considered as one of the most common causes of 
LUTS. These symptoms, which include dribbling and urgency with leaking, noctu-
ria, and difficulty in urinating, can also impact the sexual function, probably due to 
impact on QoL [70].
7.  Medical and surgical therapy for LUTS and its impact on sexual 
function
The efficacy of all currently available treatments for LUTS is well studied. 
However, the negative impact of them on erectile function is under evaluation. 
Behavior modification therapies and phytotherapies seem to have minimal or no 
impact on sexual function, and even less efficacy on LUTS treatment. On the other 
hand, α-blockers, 5α-reductase inhibitors, and prostatic surgery are associated with 
improvement in LUTS, but they usually have a negative impact on the sexual func-
tion [68]. Many clinical trials have reported on the efficacy of chronic treatment 
with phosphodiesterase type 5 inhibitors (PDE5-Is), either alone or in combination 
with other therapies, in treating LUTS in men with or without ED [71].
α-Blockers such as alfuzosin, doxazosin, tamsulosin, and silodosin have shown 
similar efficacy, but their effect on sexual function is variable. They seem to have 
a slightly positive impact on erectile function. However, they can have a negative 
impact on orgasmic function and ejaculation [72]. Originally, the abnormal ejacu-
late was thought to be retrograde. However, it seems likely to be due to a decrease 
or absence of seminal fluid, possibly by a central effect. α-Blockers decrease the 
prostate secretion and inhibit the contraction of seminal vesicles as both effects are 
mediated by the sympathetic adrenergic system.
5α-Reductase inhibitors (5-ARIs) are usually offered to men with LUTS who 
have a prostate estimated to be larger than 40 ml and who are considered to be at 
high risk of progression [73–75]. Compared to α-blockers, 5-ARIs have a greater 
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impact on sexual function. The side effects most frequently notified are reduced 
libido, ED, and ejaculation disorders such as dry orgasm, ejaculation failure, or 
decreased semen volume [76–78]. It must be mentioned that the effect of 5-ARIs on 
ejaculatory function is currently poorly studied.
Regarding surgical options, transurethral resection of the prostate (TURP) 
and transurethral incision of the prostate (TUIP) are the gold standard surgical 
techniques for BPH/BOO treatment. Dry orgasm after these operations ranges 
from 30.4 to 96.9% and 6.1 to 55.1%, respectively. Heterogeneous data are reported, 
mainly because only a few studies analyzed these rates [79–81] in a prospective 
fashion. ED has been found ranging from 3.4 to 32.4% [80, 81] after TURP.
Laser procedures, such as GreenLight photoselective vaporization of the prostate 
(PVP) and holmium laser enucleation of the prostate (HoLEP) are widely offered 
for BOO/BPH as well. The impact of GreenLight on sexual function seems to be 
close to that of TURP. One single study, comparing these two prostatic surgery 
techniques, reported no significant difference in the rate of retrograde ejaculation 
[82]. There is also no difference reported between TURP and PVP for erectile func-
tion [83, 84]. HoLEP seems to have comparable results. Specifically, the incidence of 
retrograde ejaculation and erectile dysfunction is comparable between HoLEP and 
TURP [85, 86]. It is reported that almost 75% of sexually active patients have retro-
grade ejaculation after HoLEP. Currently, both GreenLight and HoLEP surgeons are 
trying to develop ejaculation preserving techniques [87, 88].
Transurethral thermotherapy and microwave techniques such as transurethral 
needle ablation (TUNA) seem to have lower rates of retrograde ejaculation com-
paring to TURP. A few studies report that the incidence of retrograde ejaculation 
seems to be much lower compared to TURP, with no reported cases in the TUNA 
cohort, compared to the 45% of the TURP arm [89–91]. Urolift/prostatic urethral 
lift (PUL) is an alternative option and has shown positive results in terms of sexual 
function [92].
Currently, because of the increase in life expectancy, patients with LUTS often 
wish to preserve or to improve their sexual function according to their treatments. 
Physicians may focus on the symptoms without considering patients’ wishes and 
expectations. In those cases, despite successful treatment, many patients still 
complain about their QoL due to the procedure or medication side effects.
8. Medical therapy for ED and its impact on LUTS
Phosphodiesterase type 5 (PDE5) is expressed in the whole of the lower urinary 
tract, including the urethra, prostate, and bladder. All these organs are targets of 
PDE5-Is [93–96]. PDE5 is prominently localized in the stroma and in the vascular 
bed (endothelial and smooth muscle cells), suggesting the action of PDE5-I on 
smooth muscle contraction and blood flow.
McVary et al. [97], in 2007, evaluated the safety and efficacy of tadalafil for the 
treatment of LUTS in men with or without ED, for the first time. A total of 479 
patients were screened. After a 4-week washout and 4-week placebo run-in period, 
281 were randomly assigned to a 6-week treatment with once-daily placebo or 
tadalafil 5 mg. After 6 weeks, the remaining 261 patients were assigned to continue 
with placebo for another 6 weeks (a total of 12 weeks of once-daily placebo treat-
ment) or to dose escalate tadalafil to 20 mg once daily. Of 143 placebo-assigned 
patients, 121 (84.6%) were sexually active, 84 (59.2%) had no erectile dysfunc-
tion, and 76 (53.1%) were sexually active despite ED. On the other hand, 138 men 
treated with 5 or 20 mg tadalafil, 107 (77.5%) were sexually active, 99 (71.7%) had 
normal sexual function, and 80 (58.0%) were sexually active despite ED. The IPSS 
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(including the IPSS-QoL question) and BII questionnaires were used in order to 
evaluate LUTS. Maximum urinary flow rate (Qmax) and average urinary flow rate 
(Qave) of free uroflowmetry were record and post-void residual urine (PVR) was 
measured by ultrasound after uroflowmetry. The erectile function (EF) domain of 
the International Index of Erectile Function (IIEF) questionnaire (questions 1–5 
and 15) was used to estimate the sexual function.
Since 2007, numerous studies proved the safety and efficacy of PDE5s as a medi-
cal therapy for both LUTS and ED. Bora Irer et al. [98] studied LUTS, nocturia, 
SD, and the status of QoL in men with obstructive sleep apnea syndrome (OSAS). 
Patients applied continuous positive airway pressure (CPAP) treatment, which 
is one of the most effective treatments for OSAS, supplying positive air pressure 
for the opening of the respiratory tract and keeping high saturation of oxygen. 
Changes in IPSS, IIEF, Overactive Bladder Syndrome Score (OABSS), International 
Consultation on Incontinence Questionnaire for Male LUTS (ICIQ-MLUTS), 
Neuro-quality of life score (Nqol), 36-item Short Form Health Survey (SF-36), and 
Benign Prostatic Hyperplasia Impact Index (BII); the frequency of nocturia; and 
night-time urine volume were reported. After CPAP treatment, significant changes 
and improvements on these symptoms and QoL were observed. It has been shown 
that the frequency of nocturia decreases and erectile function and QoL improves in 
patients with OSAS under CPAP treatment [99, 100].
9. Conclusion
SD and LUTS are confirmed to have a strong connection. It is implied by com-
mon pathophysiological paths that seem to link these two complications, which 
have a great impact on a significant percentage of urological patients. For men, 
PDE5s inhibitors are the milestone of medical treatment for ED and LUTS. Their 
safety and efficacy are widely accepted. More studies need to support this relatively 
new field of research for both LUTS and SD, and new treatments may be used as an 
alternative in near future.
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